domingo, 2 de agosto de 2020

Coronavirus [NEW TOPIC PAGE]

Hot Topics of the Day|PHGKB

Coronavirus

We developed and validated COVID-19 Estimated Risk (COVER) scores that quantify a patient's risk of hospital admission (COVER-H), requiring intensive services (COVER-I), or fatality (COVER-F) in the 30-days following COVID-19 diagnosis. We analyzed a federated network of electronic medical records and claims data from 14 data sources and 6 countries.
A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun. The vaccine, known as mRNA-1273, was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna, Inc., and the National Institute of Allergy and Infectious Diseases (NIAID).
Mutations in SARS-CoV-2 might help the virus to thwart potent immune molecules. The blood of many people who recover from COVID-19 contains immune-system molecules called neutralizing antibodies that disable particles of the new coronavirus. Most such antibodies recognize the new coronavirus’s spike protein, which the virus uses to infect cells.
Predicting the Emergence of SARS-CoV-2 Clades
S Jain et al, BIORXIV, July 27, 2020

No hay comentarios:

Publicar un comentario